Research articlePublished 30 Jun 2023
Serum Interleukin-6 as a Potential Indicator of Severity in Covid-19 Patients: A Cohort Study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Interleukin-6 is produced by a variety of cell types, but the most important sources are macrophages and monocytes at inflammatory sites. IL-6 is the chief stimulator for the production of most acute-phase proteins, whereas the other implicated cytokines influence subgroups of acute-phase proteins. IL-6 stimulates the inflammatory and auto-immune processes in many diseases such as multiple sclerosis, Neuro Myelitis Optica Spectrum Disorder (NMOSD), diabetes, atherosclerosis, depression, Alzheimer's disease, systemic lupus erythematosus, multiple myeloma, prostate cancer, Behçet's disease, rheumatoid arthritis, and intracerebral hemorrhage. Hence, there is an interest in developing anti-IL-6 agents as therapy against many of these diseases. The first such is tocilizumab, which has been approved for rheumatoid arthritis. Castleman's disease and systemic juvenile idiopathic arthritis. Others are in clinical trials
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Medical Research & Health Sciences
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Naval Kishor Lodha”
- BylineArticles whose byline prints “Krishna Murari”
- BylineArticles whose byline prints “Biramch”
- BylineArticles whose byline prints “Mewara”
- BylineArticles whose byline prints “Gopal Sharma”
- BylineArticles whose byline prints “Mahendra Verma”